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Introduction
Despite recent improvements in the prognosis and treatment
of acute myeloid leukemia (AML), disease relapse continues to
affect most patients who are not allografted.1 Autologous
hematopoietic stem cell transplantation (ASCT) offers an alter-
native possibility of delivering high-dose myeloablative treat-
ment in AML. Several historical randomized trials have reported
significantly lower relapse incidences after ASCT than after con-
ventional chemotherapy. Unfortunately ASCT is associated
with a non-negligible non-relapse mortality linked to the use of
total body irradiation or the combination of oral busulfan with
cyclophosphamide, as well as slow kinetics of engraftment with
bone marrow grafts. The use of peripheral blood stem cells
since 1994 has resulted in more rapid engraftment kinetics and
lower rates of non-relapse mortality.2
Busulfan is an alkylating agent that has been used as a
chemotherapeutic agent since 1950. High-dose busulfan com-
bined with cyclophosphamide is frequently used for
chemotherapy dose intensification in patients undergoing
ASCT for AML3,4 and other malignant and non-malignant dis-
eases. Until recently busulfan was available only in an oral form
and given four times daily. Although busulfan was shown to be
effective when used in this regimen, the therapeutic potential of
the oral drug is compromised by unpredictable exposure.5,6 A
high area under the curve of busulfan plasma concentration ver-
sus time is associated with a high-risk of regimen-related toxic-
ity and, in particular, sinusoidal obstructive syndrome/hepatic
veno-occlusive disease.6-9 Conversely, low busulfan concentra-
tions are associated with a higher risk of graft rejection and
leukemia relapse.6,10-13
To reduce both intra- and inter-individual variability of busul-
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Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell
transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral
busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who
received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%),
and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and
relapse incidence were 67±2%, 53±2%, and 40±2%, respectively. The non-relapse mortality rate at 2 years was
7±1%. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2
years did not differ significantly between the 815 patients transplanted in first complete remission (52±2% and
40±2%, respectively) and the 137 patients transplanted in second complete remission (58±5% and 35±5%, respec-
tively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival
was 63±4% in patients with good risk cytogenetics, 52±3% in those with intermediate risk cytogenetics, and 37
± 10% in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2% ver-
sus 56±3%; P<0.001), leukemia-free survival (61±3% versus 45±3%; P<0.001), relapse incidence (35±2% versus
45±3%; P<0.005), and non-relapse mortality (4±1% versus 10±2%; P<0.001) than older patients. The combination
of intravenous busulfan and high-dose melphalan was associated with the best overall survival (75±4%). Our
results suggest that the use of intravenous busulfan simplifies the autograft procedure and confirm the usefulness
of autologous stem cell transplantation in acute myeloid leukemia. As in allogeneic transplantation, veno-occlusive
disease is an uncommon complication after an autograft using intravenous busulfan.
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ABSTRACT
fan pharmacokinetics, an intravenous formulation of busul-
fan has recently been developed. In adults, intravenous
busulfan has shown predictable and consistent pharmacoki-
netic profiles with acceptable toxicity.14-16 In addition, it is
easier to administer and is associated with lower rates of
sinusoidal obstructive syndrome, partially due to the elimi-
nation of first-pass metabolism, in children and in allogeneic
stem cell transplantation.
In adults with AML, historical series of ASCT from vari-
ous institutions,17 retrospective surveys from the European
Group for Blood and Marrow Transplantation (EBMT)18-22
and the Center for International Blood and Marrow
Transplant Research,23 and randomized trials24,25 have
revealed long-term leukemia-free survival rates of 45-55% in
patients transplanted in first remission and 25-35% for those
transplanted in second remission.26 However, in contrast to
the considerable experience using oral busulfan in high-dose
regimens, no studies have reported outcomes using intra-
venous busulfan-based conditioning regimens for ASCT. For
that reason the EBMT Acute Leukemia Working Party eval-
uated outcomes of adult patients who underwent ASCT fol-
lowing a high-dose regimen containing intravenous busul-
fan.
Methods
The study design was approved by the Acute Leukemia
Working Party, in accordance with the EBMT guidelines for retro-
spective studies.
Data from 952 adult AML patients undergoing intravenous
busulfan-based conditioning prior to ASCT from January 2003 to
December 2011 were reported to the Acute Leukemia Working
Party of the EBMT. The diagnosis of AML was based on morpho-
logical criteria according to the French–American–British classifica-
tion. The median age of the patients was 50.5 years (range, 18–77),
56% of the patients were male, and the median transplant year was
2009 (2003–2011) (Table 1). Internal tandem duplication of the FLT3
gene was positive in 32 (22%) of the 142 patients assessed. The
median follow-up was 16 months (range, 1–110 months). The con-
ditioning regimen consisted of intravenous busulfan median total
dose 12.8 mg/kg; (range, 6.4–16.3) combined with cyclophos-
phamide (total dose 120 mg/kg, n=517), melphalan (140 mg/m2,
n=234), VP-16 (n=82), idarubicin (n=46), or other agents (n=73).
End-point definitions and statistical analysis 
Four outcomes were evaluated in this series: (i) non-relapse mor-
tality, defined as death without previous relapse; (ii) relapse inci-
dence, defined on the basis of morphological evidence of leukemia
in bone marrow or extramedullary organs; (iii) leukemia-free sur-
vival, defined as the time interval from the transplant to first event
(either relapse or death in complete remission); and (iv) overall sur-
vival. Cumulative incidence curves were used for relapse incidence
and non-relapse mortality in a competing risks setting,27 since death
and relapse are competing events. The Gray test was used for uni-
variate comparisons.28 Probabilities of overall survival and
leukemia-free survival were calculated using the Kaplan–Meier esti-
mate,29 and the log-rank test was used for univariate comparisons.
Relationships between outcomes and patient, disease, and graft
characteristics were evaluated in multivariate analyses using the
Cox proportional hazards model.30 All tests were two-sided. The
type I error rate was fixed at 0.05 for the determination of factors
associated with time-to-event outcomes. Statistical analyses were
performed with SPSS 19 (SPSS Inc., Chicago, IL, USA) and R 2.13.2
(R Development Core Team, Vienna, Austria) software packages.
Results
Nine hundred and twenty-three patients engrafted with a
median time to neutrophil recovery (>500/mm3) of 12 days
(range, 2–110); 12 patients did not engraft, and three addi-
tional patients had a late graft failure. A total of 256 patients
died: 161 from relapse and disease progression, 45 from
infection, and 5 from hepatic veno-occlusive disease. At 2
years, the overall survival rate was 67±2%, the leukemia-
free survival rate was 53±2%, the relapse incidence was 40±
2%, and the non-relapse mortality rate was 7±1%. Of the
five patients who died from sinusoidal obstructive syn-
drome, four were transplanted in first complete remission
and one in second complete remission; the doses of intra-
venous busulfan used in these patients were 16 mg/kg (n=1),
12.8 mg/kg (n=3), and 12 mg/kg (n=1).
The univariate analyses showed that there were no differ-
ences in outcome for patients transplanted in first complete
remission or second complete remission (Table 2). For
patients transplanted in first complete remission, the overall
survival rate was 67±2%, the leukemia-free survival rate
was 52±2%, and the relapse incidence was 40±2% (Figure
1). For patients transplanted in second complete remission,
the overall survival rate was 69±4%, the leukemia-free sur-
vival rate was 58±5%, and the relapse incidence was 35±5%
(Figure 2). The non-relapse mortality rate did not differ
between the two groups of patients (first complete remis-
sion 7±1% versus second complete remission 6±2%). As
expected, cytogenetic risk classification was predictive of
outcome, with significantly better results for the good risk
group compared with intermediate risk and poor risk groups
(overall survival: 75±2% versus 69±3% versus 46±10%,
Table 1. Patient and disease characteristics.
Patient characteristics                             Patients (n=952)
Gender                                                                 Male                                          531(56%)
                                                                                Female                                     421 (44%)
Median age at transplant, years (range)                                                      50.5 (18–77)
Median year of transplant (range)                                                           2009 (2003–2011)
Disease characteristics
French–American–British classification, %
                                                                                M0                                                     5
                                                                                M1                                                   18.5
                                                                                M2                                                    28
                                                                                M3                                                    11
                                                                                M4                                                    20
                                                                                M5                                                    15
                                                                                M6                                                     2
                                                                                M7                                                    <1
                                                                                Missing                                            23
Cytogenetic classification, %                          Good                                                36
                                                                                Intermediate                                 58
                                                                                Poor                                                  6
Status at the time of transplant, n.                CR1                                                  815
                                                                                CR2                                                  137
Conditioning regimen, n.                                  IV BU+cyclophosphamide        517
                                                                                IV BU+melphalan                        234
                                                                                IV BU+etoposide                         82
                                                                                IV BU+idarubicin                         46
Classified according to the European Organization for Research and Treatment of Cancer. CR1:
first complete remission; CR2: second complete remission; IV: intravenous; BU: busulfan.
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P=0.003; leukemia-free survival: 63±4% versus 52±3% versus
37±10%, P=0.01; relapse incidence 31±4% versus 43±3%
versus 55±11%, P=0.02). Younger patients (≤50 years old)
had better outcomes than older patients (overall survival:
77±2% versus 56±3%, P<0.001; leukemia-free survival:
61±3% versus 45±3%, P<0.001; relapse incidence: 35±2%
versus 45±3%, P=0.005) (Figure 3). The non-relapse mortali-
ty was 4±1% in patients ≤50 years, and 10±2% in patients
>50 years (P=0.0002). 
Results of multivariate analysis (Table 3) showed that age
was a significant prognostic factor for overall survival,
leukemia-free survival, relapse incidence, and non-relapse
mortality, and cytogenetic classification was a significant
prognostic factor for overall survival and leukemia-free sur-
vival. The combination of intravenous busulfan and high-
dose melphalan was associated with a better overall survival
(P=0.03; hazard ratio: 0.6; 95% confidence interval: 0.38–
0.95).
Discussion
ASCT has been widely used for consolidation chemother-
apy in patients with AML in first or second complete remis-
sion in the past decades. Indeed, the EBMT registry present-
ly contains information on more than 17,000 autografts for
AML. Although ASCT for AML remains a therapeutic
option, it has become less popular for two major reasons.
The first reason is the high relapse incidence post-ASCT and
the risk of late relapse (11% at 5 years, 16% at 10 years) in
patients still in complete remission 2 years post-ASCT, sug-
gesting a possible role for some maintenance therapy.31 A
second reason is the recent development of allogeneic stem
cell transplantation with reduced-intensity conditioning,
which has made transplantation feasible in older patients
(≤70 years of age) and enabled the use of alternative donors
e.g., HLA-matched unrelated donors, cord blood, and even
haplo-mismatched family donors, allowing the possibility of
an allograft for almost all patients. Allogeneic stem cell trans-
plantation is associated with a lower relapse incidence from
the graft-versus-leukemia effect but unfortunately is also
associated with higher rates of non-relapse mortality, graft-
versus-host disease, and infections; surviving recipients of
allogeneic grafts do, therefore, tend to have a poorer quality
Figure 1. Outcomes of patients with AML autografted in first com-
plete remission using a pretransplant conditioning regimen contain-
ing intravenous busulfan.
Figure 2. Outcomes of patients with AML autografted in second com-
plete remission using a pretransplant conditioning regimen contain-
ing intravenous busulfan.
Table 2. Univariate analysis of prognostic factors.
Univariate 2-year Leukemia- Overall Relapse Non-relapse  
analysis outcome free survival survival incidence mortality
Status CR1 52±2 67±2 40±2 7±1
at transplant CR2+ 58±5 69±4 35±5 6±2
P 0.53 0.69 0.48 0.86
Cytogenetic Good 63±4 75±4 31±4 5±2
classification Intermediate 52±3 69±3 43±3 5±1
Poor 37±10 46±10 55±11 7±5
P 0.01 0.003 0.02 0.5
Age at ≤50 61±3 77±2 35±2 4±1
transplantation, >50 45±3 56±3 45±3 10±2
year P <0.001 <0.001 0.005 0.0002
White blood cell <Median 54±4 69±4 41±4 5±2
count at >Median 58±4 70±4 37±4 5±2
diagnosis 0.46 0.9 0.48 0.87
Sex Male 53±3 65±3 38±2 9±1
Female 54±3 69±3 41±3 5±1
P 0.9 0.29 0.38 0.06
Year of <2008 57±3 70±2 38±3 5±1
transplant ≥2008 48±3 62±3 43±3 9±2
P 0.05 0.01 0.36 0.01
Conditioning BU+ 51±2 65±2 41±2 7±1
regimen cyclophosphamide
BU+melphalan 56±4 75±4 35±3 8±2
BU+VP16 61±7 70±7 39±7 0
Other 53±5 63±5 41±5 6±2
P 0.46 0.11 0.21 0.21
CR1: first complete remission;CR2: second complete remission; BU: busulfan.
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of life compared with patients who undergo ASCT.32
Several randomized studies24,25,33-36 comparing allogeneic
stem cell transplantation using HLA-identical siblings after a
myeloablative conditioning regimen with ASCT and
chemotherapy have reported better outcomes after allo-
geneic transplantation, but they have also consistently
shown a decreased relapse incidence after ASCT compared
with conventional chemotherapy. However, to date no ran-
domized study has demonstrated the superiority of allo-
geneic transplantation using an alternative donor (unrelated
or cord blood) over ASCT. A retrospective EBMT study of
elderly patients with de novoAML found that outcomes after
allogeneic peripheral blood stem cell transplantation from
HLA-identical sibling donors with reduced-intensity condi-
tioning were similar to outcomes after autologous peripheral
blood stem cell transplantation.37
A recent retrospective study from the Center for
International Blood and Marrow Transplant Research con-
cluded that in the absence of a matched sibling donor, ASCT
may provide an acceptable alternative post-remission thera-
py for patients with AML in first complete remission.23
Furthermore results of ASCT in AML may be improved.
Several recent studies, including two retrospective surveys
from the EBMT, reported similar outcomes after ASCT and
allogeneic stem cell transplantation in patients with AML in
the good risk classification who carried an inversion on chro-
mosome 16, the t(8 ;21) translocation, or the NPM1 muta-
tion.20,21 More recently Schlenk et al.38 evaluated patients
included in prospective randomized trials with prognostical-
ly favorable AML and double CEBPA mutations. They
found that allogeneic or autologous hematopoietic stem cell
transplantation produced identical outcomes, with
leukemia-free survival and overall survival rates >70% at 4
years, which were significantly better than outcomes after
conventional chemotherapy. 
In addition, the quality of the autograft is of considerable
importance. Clinical observations from  patients with acute
promyelocytic leukemia (AML3) in second complete remis-
sion39 or acute lymphocytic leukemia expressing the BCR-
ABL transcript and receiving tyrosine kinase inhibitors40 have
shown that patients with no detectable minimal residual dis-
ease may benefit from dose intensification and autografting.
Regarding the introduction of maintenance therapy, trials in
progress41 are looking for a possible benefit from the use of
hypomethylating agents in allogeneic transplantation. This
approach may also be useful in ASCT to reduce the inci-
dence of late relapse. Overall, these considerations may sup-
port the view that patients receiving only chemotherapy
nowadays in fact should receive ASCT whenever possible,
Figure 3. Leukemia-free survival and relapse incidence according to
the patients’ age (<50 years, ≥50 years).
Table 3. Multivariate analyses*.
P Hazard ratio 95% CI
Age >50 years 0.001 1.61 1.23 2.13
CR2 vs. CR1 0.56 0.87 0.56 1.37
Year ≥2009 0.09 1.27 0.96 1.69
Conditioning
LFS BU+cyclophosphamide (reference) 1
BU+melphalan 0.14 0.76 0.53 1.10
BU+VP16 0.37 0.80 0.48 1.31
Other 0.86 1.04 0.70 1.53
Cytogenetic classification
Intermediate (reference) 1
Good 0.25 0.80 0.55 1.17
Poor 0.03 1.75 1.05 2.93
Age >50 years 0.000 2 1.448 2.784
CR2 vs. CR1 0.530 1.173 0.713 1.931
Year ≥2009 0.009 1.566 1.120 2.190
Conditioning
BU+cyclophosphamide (reference) 1
OS BU+melphalan 0.031 0.606 0.383 0.956
BU+VP16 0.779 0.919 0.511 1.654
Other 0.516 1.158 0.745 1.800
Cytogenetic classification
Intermediate (reference) 1
Good 0.291 0.782 0.496 1.234
Poor 0.002 2.397 1.380 4.162
Age >50 years 0.008 1.489 1.107 2.003
CR2 vs. CR1 0.436 0.823 0.505 1.343
Year ≥2009 0.231 1.204 0.888 1.632
Conditioning
BU+cyclophosphamide (reference) 1
RI BU+melphalan 0.116 0.729 0.491 1.081
BU+VP16 0.800 0.937 0.564 1.555
Other 0.773 1.063 0.702 1.610
Cytogenetic classification
Intermediate (reference) 1
Good 0.201 0.764 0.506 1.154
Poor 0.105 1.591 0.908 2.787
Age >50 years 0.012 2.741 1.251 6.003
CR2 vs. CR1 0.882 1.090 0.350 3.398
Year ≥2009 0.118 1.846 0.855 3.984
Conditioning
BU+cyclophosphamide (reference) 1
NRM BU+melphalan 0.923 0.957 0.393 2.328
BU+VP16 0.975 0.000 0.000 .
Other 0.869 0.911 0.304 2.733
Cytogenetic classification
Intermediate (reference) 1
Good 0.999 1.001 0.361 2.777
Poor 0.072 3.184 0.902 11.241
*485 patients with no missing values. LSF: leukemia-free survival; OS: overall survival; RI: relapse
incidence; NRM: non-relapse mortality; CR1: first complete remission;CR2: second complete
remission; BU: busulfan.
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and ASCT would be a more appropriate control than
chemotherapy alone for allogeneic transplantation with any
comparison taking into account the quality of life.
The present study is the first retrospective study to include
a large series of patients with AML receiving an intravenous
busulfan-based conditioning regimen prior to ASCT. The
absorption and bioavailability of oral busulfan are erratic and
unpredictable; therefore, monitoring busulfan levels and
making dose adjustments cannot be easily achieved with the
oral formulation.8,42-44 In contrast, the initial experience with
intravenous busulfan showed that pharmacokinetic values
are more predictable, with 85% of patients achieving and
maintaining the targeted therapeutic window (area under
the curve: 900–1500 mM/min). This allows a tight control of
plasma levels and less need for plasma level testing and dose
adjustment.14 Lee et al.45 evaluated 253 patients with malig-
nant disorders (49% with breast cancer) who underwent
ASCT after receiving a conditioning regimen of 12 mg/kg
oral busulfan, 100 mg/m2 melphalan, and 500 mg/m2
thiotepa and found that 70 (28%) experienced veno-occlu-
sive disease, which was moderate in 31 (12%) patients and
severe in 11 (4%). Our observation of fatal sinusoidal
obstructive syndrome/veno-occlusive disease in only 5% of
patients receiving intravenous busulfan is in sharp contrast
with these historical data. Similar low incidences of sinu-
soidal obstructive syndrome/veno-occlusive disease have
been claimed when using pharmacokinetics and dose adjust-
ment for oral busulfan. However, with this approach, there
is still considerable intrapatient variability with a reported
coefficient of variation of 36%;46 furthermore, this technolo-
gy is not available everywhere, so that the benefit in terms
of cost/effectiveness  concerns only selected centers. The
observation that patients autografted in second complete
remission had outcomes similar to those autografted in first
complete remission, which has never been reported in
numerous series and trials, further attests to the potential
benefits of intravenous busulfan. Recent studies evaluated
the toxicity and outcomes of intravenous busulfan-based
conditioning in patients with multiple myeloma,47 non-
Hodgkin lymphoma, neuroblastoma, and Ewing sarcoma.48
Taken together, the results demonstrated that intravenous
busulfan has high efficacy with very low toxicity; the rate of
mild-to-moderate sinusoidal obstructive syndrome was
<5% and no deaths without prior relapse (non-relapse mor-
tality) were observed. 
We recently reported for the Acute Leukemia Working
Party of the EBMT on the comparison of intravenous busul-
fan plus cyclophosphamide versus total body irradiation plus
cyclophosphamide in allotransplanted patients.49 Patients
who received intravenous busulfan plus cyclophosphamide
had lower rates of acute and chronic graft-versus-host disease
and a trend toward lower non-relapse mortality. Leukemia-
free survival did not differ significantly between the two
groups of patients. In the present retrospective study,
patients received intravenous busulfan at the recommended
dosage of 0.8 mg/kg four times a day for 4 days before
ASCT. New modalities of administered intravenous busul-
fan are being tested with only one perfusion per day.50
Likewise, high-dose melphalan is now given intravenously
over 90 to 120 minutes. In the present study patients who
received intravenous busulfan plus melphalan had a better
overall survival rate than other patients but did not differ in
terms of relapse incidence or leukemia-free survival rate.
The combination of intravenous busulfan and high-dose
melphalan may be one of the simplest conditioning regi-
mens before autografting.
Along the lines described above, there are presently three
ongoing phase 2 studies testing the role of ASCT, two  in
good and intermediate risk AML within the Spanish CET-
LAM group with a specific interest in evaluation of minimal
residual disease and in vivo purging by gemtuzumab
ozogamicin and one in good risk patients only, using intra-
venous busulfan four times a day and etoposide as a pre-
transplant regimen in South Korea. In addition, a random-
ized phase 3 study comparing ASCT with intravenous
busulfan included in the pretransplant regimen and haplo-
mismatched transplants in AML is currently underway in
China, where these two therapeutic strategies are both used,
since most families have only one child.
Based on our results we suggest that intravenous busulfan
may be an important step forward to improve results of
ASCT in patients with AML. Prospective studies comparing
intravenous busulfan-based conditioning for ASCT with
allogeneic stem cell transplantation using matched unrelated
or matched-related donors should be performed.
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